SCI Pharmtech, Inc. (TPE:4119)

Market Cap	6.21B -13.5%
Revenue (ttm)	1.26B -18.8%
Net Income	60.12M -87.5%
EPS	0.50 -87.7%
Shares Out	119.51M
PE Ratio	103.92
Forward PE	n/a
Dividend	0.75 (1.43%)
Ex-Dividend Date	Jul 1, 2026

Volume	58,163
Open	51.80
Previous Close	52.30
Day's Range	51.80 - 52.70
52-Week Range	39.60 - 63.20
Beta	-0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2025, SCI Pharmtech's revenue was 1.34 billion, a decrease of -11.81% compared to the previous year's 1.52 billion. Earnings were 107.37 million, a decrease of -79.92%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error